BioHarvest Sciences (BHST) Competitors $5.95 +0.64 (+12.05%) As of 02/21/2025 03:46 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrends BHST vs. ESPR, MBX, TERN, FHTX, CYRX, ANNX, XOMA, CRVS, TRVI, and CMPSShould you be buying BioHarvest Sciences stock or one of its competitors? The main competitors of BioHarvest Sciences include Esperion Therapeutics (ESPR), MBX Biosciences (MBX), Terns Pharmaceuticals (TERN), Foghorn Therapeutics (FHTX), Cryoport (CYRX), Annexon (ANNX), XOMA (XOMA), Corvus Pharmaceuticals (CRVS), Trevi Therapeutics (TRVI), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical preparations" industry. BioHarvest Sciences vs. Esperion Therapeutics MBX Biosciences Terns Pharmaceuticals Foghorn Therapeutics Cryoport Annexon XOMA Corvus Pharmaceuticals Trevi Therapeutics COMPASS Pathways Esperion Therapeutics (NASDAQ:ESPR) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings. Do institutionals & insiders hold more shares of ESPR or BHST? 47.4% of Esperion Therapeutics shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer ESPR or BHST? In the previous week, Esperion Therapeutics had 9 more articles in the media than BioHarvest Sciences. MarketBeat recorded 10 mentions for Esperion Therapeutics and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of -0.16 beat Esperion Therapeutics' score of -0.35 indicating that BioHarvest Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BioHarvest Sciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ESPR or BHST? Esperion Therapeutics currently has a consensus target price of $6.75, indicating a potential upside of 269.86%. BioHarvest Sciences has a consensus target price of $13.00, indicating a potential upside of 118.49%. Given Esperion Therapeutics' higher probable upside, research analysts clearly believe Esperion Therapeutics is more favorable than BioHarvest Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50BioHarvest Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ESPR or BHST? Esperion Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500. Is ESPR or BHST more profitable? Esperion Therapeutics has a net margin of -29.37% compared to BioHarvest Sciences' net margin of -76.65%. Company Net Margins Return on Equity Return on Assets Esperion Therapeutics-29.37% N/A -10.77% BioHarvest Sciences -76.65%N/A -85.16% Which has stronger earnings & valuation, ESPR or BHST? BioHarvest Sciences has lower revenue, but higher earnings than Esperion Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEsperion Therapeutics$116.33M3.09-$209.25M-$0.64-2.85BioHarvest Sciences$12.67M7.71-$12.56M-$1.25-4.76 Does the MarketBeat Community believe in ESPR or BHST? Esperion Therapeutics received 623 more outperform votes than BioHarvest Sciences when rated by MarketBeat users. However, 100.00% of users gave BioHarvest Sciences an outperform vote while only 70.15% of users gave Esperion Therapeutics an outperform vote. CompanyUnderperformOutperformEsperion TherapeuticsOutperform Votes62570.15% Underperform Votes26629.85% BioHarvest SciencesOutperform Votes2100.00% Underperform VotesNo Votes SummaryEsperion Therapeutics beats BioHarvest Sciences on 11 of the 17 factors compared between the two stocks. Get BioHarvest Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for BHST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BHST vs. The Competition Export to ExcelMetricBioHarvest SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.22M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-4.765.8226.1519.13Price / Sales7.71268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book-5.516.717.644.62Net Income-$12.56M$138.55M$3.19B$245.94M7 Day Performance2.94%-2.63%-2.11%-2.62%1 Month Performance7.21%-2.33%-0.49%-2.15%1 Year PerformanceN/A-5.33%16.44%12.95% BioHarvest Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BHSTBioHarvest SciencesN/A$5.95+12.1%$13.00+118.5%N/A$87.22M$12.67M-4.76N/AGap UpHigh Trading VolumeESPREsperion Therapeutics4.4382 of 5 stars$1.86-0.5%$6.75+262.9%-30.1%$366.49M$295.45M-2.91200Gap DownMBXMBX Biosciences2.5161 of 5 stars$10.41+15.8%$37.25+257.8%N/A$347.90MN/A0.0036Insider TradeNews CoveragePositive NewsTERNTerns Pharmaceuticals4.3948 of 5 stars$4.06-0.5%$18.30+350.7%-50.4%$344.86MN/A-3.4440FHTXFoghorn Therapeutics2.7058 of 5 stars$6.13-0.5%$13.17+114.8%-12.4%$340.89M$34.15M-3.19120Gap UpCYRXCryoport2.5899 of 5 stars$6.73+0.3%$12.29+82.6%-61.4%$332.67M$226.11M-1.991,170Positive NewsANNXAnnexon2.5599 of 5 stars$3.07+2.0%$15.80+414.7%-42.8%$327.23MN/A-2.9260News CoverageGap UpXOMAXOMA4.5453 of 5 stars$26.76-1.1%$72.00+169.1%-4.0%$315.23M$4.76M-7.6910CRVSCorvus Pharmaceuticals2.6919 of 5 stars$4.88-0.8%$12.38+153.6%+82.2%$313.57MN/A-5.2530News CoveragePositive NewsTRVITrevi Therapeutics2.7375 of 5 stars$4.07+1.5%$9.31+128.8%+73.6%$312.86MN/A-9.2520News CoverageGap UpCMPSCOMPASS Pathways1.7221 of 5 stars$4.57+3.4%$30.60+569.6%-57.6%$312.68MN/A-2.08120Gap Up Related Companies and Tools Related Companies Esperion Therapeutics Competitors MBX Biosciences Competitors Terns Pharmaceuticals Competitors Foghorn Therapeutics Competitors Cryoport Competitors Annexon Competitors XOMA Competitors Corvus Pharmaceuticals Competitors Trevi Therapeutics Competitors COMPASS Pathways Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BHST) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioHarvest Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioHarvest Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
